HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PCNU: phase II evaluation in advanced colorectal carcinoma.

Abstract
PCNU, a N-(2-chloroethyl)-N-nitrosourea, was administered to 37 previously treated patients with metastatic adenocarcinoma of the colon and rectum. The drug dose was 100 mg/m2, intravenously, over one hour for good risk patients and 75 mg/m2 for poor risk patients. Poor risk patients were defined as patients over 65 years of age or having liver enzymes greater than twice normal. The infusion was repeated at 6 week intervals. Seventeen patients (median performance status 80%) received PCNU at the 100 mg/m2 dose; 20 patients (median performance status 70%) received PCNU at the 75 mg/m2 dose. Complete responses were not observed. One patient treated with 100 mg/m2 achieved a partial response. Toxicity was primarily hematological with life-threatening leukopenia and thrombocytopenia observed in six patients. PCNU administered in the described dose schedule demonstrated little therapeutic efficacy in this patient population.
AuthorsR Pazdur, M K Samson, L H Baker
JournalInvestigational new drugs (Invest New Drugs) Vol. 6 Issue 2 Pg. 93-5 (Jun 1988) ISSN: 0167-6997 [Print] United States
PMID3170134 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • Nitrosourea Compounds
  • 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea
Topics
  • Adenocarcinoma (drug therapy)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Colonic Neoplasms (drug therapy)
  • Drug Evaluation
  • Humans
  • Middle Aged
  • Nitrosourea Compounds (adverse effects, therapeutic use)
  • Rectal Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: